Newcastle disease virus oncolysate in the management of stage III malignant melanoma

Viral Therapy of Human Cancers

Volumn , Issue , 2004, Pages 677-690

  Cassel, William A ^a   Murray, Douglas R ^a   Olkowski, Zbigniew L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84969158416     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (36)

1. Webb HE, Smith CEG. Viruses in the treatment of cancer Lancet 1970; 1:1206-1209.
2. Nemunaitis J. Live viruses in cancer treatment Oncology 2002; 16:1483-1492.
3. Sharpless GR, Davies MC, Cox HR. Antagonistic action of certain neurotropic viruses toward a lymphoid tumor in chickens with resulting immunity Proc Soc Exp Biol Med 1950; 78: 270-275.
4. Koprowski H, Love R, Koprowska I. Enhancement of susceptibility to viruses in neoplastic tissues Tex Rep Biol Med 1957; 15:559-576.
5. Lindenmann J, Klein PA. Viral oncolysis: Increased immunoge- nicity of host cell antigens associated with influenza virus J Exp Med 1967; 126:93-108.
6. Svet-Moldavsky GJ, Hamburg VP. An approach to the immunological treatment of tumors by artificial hetrogenization. In: Harris JC, Ed. Specific Tumor Antigens (UICC Monograph Se- ries, vol 2). Copenhegen: Munksgaard, 1967:323-327.
7. Kobayashi H, Kodama T, Gotha E. Xenogenization of tumor cells Hokkaido Univ Med Libr Ser 1977; 9:1-24.
8. Boone CW, Paranjpe M, Orme T, Gillette R. Virus-augmented tumor transplantation antigens: Evidence for a helper antigen mechanism Int J Cancer 1974; 13:543-551.
9. Sinkovics JG, Gonzales F, Campos LT, Kay HD, Shirato E, Gy- orkey F. Immunology of human sarcomas Abstracts of the An- nual Meeting of the American Society of Microbiology 1974:206.
10. Cassel WA, Murray DR, Torbin AH, Olkowski ZL, Moore ME. Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immuno- logic responses Cancer 1977; 40:672-679.
11. Austin FC, Boone CW. Virus augmentation of the antigenicity of cell extracts Adv Cancer Res 1979; 30:301-345.
12. Cassel WA, Garrett RE. Newcastle disease virus as an antineo- plastic agent Cancer 1965; 18:863-868.
13. Cassel WA, Garrett RE. Tumor immunity after viral oncolysis J Bacteriol 1966; 92:792.
14. Merigan TC, De Clereq E, Finkelstein MS, Clever L, Walker S, Waddell DJ. Clinical studies employing interferon inducers in man and animals Ann NY Acad Sci 1970; 173:746.
15. Lorence RM, Rood PA, Kelly KW. Newcastle disease virus as an antineoplastic agent: Induction of tumor necrosis factor and augmentation of its cytotoxicity J Natl Cancer Inst 1988; 80: 1305.
16. Nossal GJV. The mechanism of action of antigens Australas Ann Med 1965; 14:321.
17. Notkins AL, Mergenhagen SE, Rizzo AA, Scheele C, Waldman TA. Elevated gamma-globulin and increased antibody production in mice infected with lactic dehyrrogenase virus J Exp Med 1966; 123:349-364.
18. Weir DM. The immunological consequences of cell death Lancet 1967; 2:1071-1073.
19. Schirrmacher V, Ahlert T, Heicappell R, Appelhaus B, Hoegen P. Successful application of non-oncogenic viruses for antimeta static cancer immunotherapy Cancer Rev 1986; 5:19-49.
20. Lindenmann J, Klein PA. Immunological aspects of viral oncolysis Recent Results Cancer Res 1967; 9:1-84.
21. Horak A, Horvath J, Sinkovics JG, Pendleton S, Pritchard M. Antiviral and antimelanoma immune reactions in patients actively immunized with melanoma-NDV oncolysates, St. Jo- seph’s Cancer Institute and University of South Florida Melanoma Conference, 1998, Tampa, FL.
22. Murray DR, Cassel WA, Torbin AH, Olkowski ZL, Moore ME. Viral oncolysate in the management of malignant melanoma. II. Clinical studies Cancer 1977; 40:680-686.
23. Cassel WA, Murray DR. A ten-year follow-up of stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate Med Oncol 1992; 9:169-171.
24. Callery C, Cochran AJ, Roe DL, Rees W, Nathanson SD, Bened- etti JK, Elashoff RM, Morton DL. Factors prognostic for survival in patients with malignant melanoma spread to regional lymph nodes Ann Surg 1982; 196:69-75.
25. Bevilacqua RG, Coit DG, Rogatko A, Younes RN, Brennan MF. Auxillary dissection in melanoma. Prognostic variables in node- positive patients Ann Surg 1990; 212:125-131.
26. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes Ann Surg 1991; 214:491-499.
27. Morton DL, Foshag LJ, Hoon DSB, Nizze JA, Wanek LA, Chang C, Davtyan DG. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine Ann Surg 1992; 215:463-482.
28. Roses DF, Harris MN, Grunberger I. Selective surgical management of cutaneous melanoma of the head and neck Ann Surg 1980; 192:629-632.
29. Cassel WA, Murray DR. Viral oncolysate in the treatment of regional metastases of melanoma. In: Larson DL, Ballantyne AJ, Guillamondegui OM, Eds. Cancer in the Neck. New York: Macmillan Publishing Company, 1986:235-242.
30. Cassel WA, Weidenheim KM, Campbell WG, Murray DR. Inflammatory mononuclear cell infiltrates in cerebral metastases during concurrent therapy with viral oncolysate Cancer 1986; 57:1302-1312.
31. Madajewicz S, Karakousis C, West CR, Caracandas J, Avel- lanosa AM. Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience Cancer 1984; 53: 2550-2552.
32. Balch CM, Milton GW, Shaw HM, Soong S. Cutaneous Melanoma. Philadelphia: JB Lippincott, 1985.
33. McCann WP, Weir BKA, Elvidge AR. Long-term survival after removal of metastatic malignant melanoma of the brain J Neurosurg 1968; 28:483-487.
34. Olkowski ZL. The role of human 99mTC labeled cytotoxic lym- phocytes in radioimmunodetection and potential radioimmuno- therapy of malignant melanoma Immunoconjugates Radio- pharmaceuticals 1991; 4:55.
35. Batliwalla FM, Bateman BA, Serrano D, Murray DR, Macphail S, Maino VC, Ansel JC, Gregersen PK, Armstrong C. A 15- year follow-up of AJCC stage III malignant melanoma patients treated with Newcastle disease virus (NDV) oncolysate and de- termination of alterations in the CD8 T cell repertoire Mol Med 1998; 4:783-794.
36. Sprakel B, Stenschke F, Unnewehr M, Ladas A, Senninger N. Prognosis of malignant melanoma following dissection of regional lymph node metastases Der Chirurg 2003; 74:55-60.